First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. e14504
• Main Authors: Cheng, Ying, Wu, Lihua, Chai, Xiaoli, Wang, Qiming, Liu, Qinghua, Fan, Lianlian, Shi, Jianhua
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

e14504Background: Multiple groups have shown that TIGIT contributes to immune-tolerance by inhibiting immune responses mediated by T cells and NK cells through binding its ligand, CD155 (PVR), on antigen-presenting cells and a variety of non-hematopoietic cell types including tumor cells. ZG005, a P...